June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Longitudinal analysis of Optical Coherence Tomography Angiography in Macular Telangiectasia Type 2
Author Affiliations & Notes
  • Lukas Goerdt
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Julie Jungblut
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Jose Luis Rodriguez
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Kristina Hess
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
    Ophthalmology, Universitat Basel, Basel, Basel-Stadt, Switzerland
  • Philipp Herrmann
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Frank G Holz
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Maximilian Wilhelm Maria Wintergerst
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Footnotes
    Commercial Relationships   Lukas Goerdt BioEQ, Code C (Consultant/Contractor), Novartis, Bayer, Code R (Recipient); Julie Jungblut None; Jose Luis Rodriguez None; Kristina Hess None; Philipp Herrmann Novartis, Bayer, Allergan, Code F (Financial Support); Frank Holz Acucela, Apellis, Bayer, Boehringer-Ingelheim, BioEQ, Roche, Geuder, Grayburg, Gyroscope, Heidelberg Engineering, IvericBio, Kanghong, LinBioscience, Novartis, Oxurion, Pixium Vision, Stealth BioTherapeutics, Zeiss, Code C (Consultant/Contractor), Acucela, Allergan, Apellis, Bayer, BioEQ, CenterVue, Ellex, Reoche, Geuder, Heidelberg Engineering, IvericBio, Kanghong, NightStarX, Novartis, Optos, Pixium Vision, Zeiss, Code F (Financial Support), GRADE Reading Center Bonn, Code O (Owner); Maximilian Wintergerst Heine Optotechnik GmbH, Code C (Consultant/Contractor), Digi Sight Technologies, Heine Optotechnik GmbH, Berlin Chemie AG, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2540. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lukas Goerdt, Julie Jungblut, Jose Luis Rodriguez, Kristina Hess, Philipp Herrmann, Frank G Holz, Maximilian Wilhelm Maria Wintergerst; Longitudinal analysis of Optical Coherence Tomography Angiography in Macular Telangiectasia Type 2. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2540.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess longitudinal optical coherence tomography angiography (OCT-A) findings and its prognostic value for disease progression in Macular Telangiectasia Type 2 (MacTel).

Methods : Participants underwent a comprehensive ophthalmologic examination and multimodal imaging including color fundus photography (CFP), fluorescein angiography, OCT and OCT-A. Eyes were classified according to the CFP-based staging system by Gass and Blodi. Automated quantitative analyses of vessel density (VD), skeleton density (SD) vessel diameter index (VDI) were performed in the superficial (SRL) and deep (DRL) retinal as well as the avascular layer (ARL). Choriocapillaris was assessed for non-perfused area (CCNPA). Linear mixed effects models (LMEM) correcting for age, sex and the nested data structure of two eyes within one patient were employed to assess for differences between stable and progressing eyes and to investigate the impact on disease progression of each parameter.

Results : A total of 122 eyes of 61 patients (35 female, mean age 62.33 ± 10.15 years) were included in this study. There was a trend towards reduced SRL VD, SRL SD, and DRL SD in eyes which experienced disease progression compared to eyes which remained stable (p = 0.058, p = 0.055, and p = 0.071, respectively) during the mean observation period of 23 months (± 7.83 months). No differences were present in VDI and CCNPA. In a LMEM baseline BCVA was prognostic for future disease stage progression (p < 0.001). Also, SRL VD may be prognostic for future disease stage progression, however no statistical significance could be reached (p = 0.051). Future central retinal thickness was best predicted by the presence/absence of EZ loss at baseline (p < 0.012).

Conclusions : Quantitative OCT-A parameters showed a trend towards reduction in eyes that progressed to a more severe MacTel stage. Baseline BCVA, EZ loss, and SRL VD could serve as prognostic imaging biomarkers for clinical monitoring and future interventional clinical trials in MacTel. Longitudinal studies on a larger sample size are warranted.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×